Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
16 jaar Canadian Hemophilia Prophylaxis Study: primaire profylaxe ‘op maat’
jun 2018 | Benigne hematologie